Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 547 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... November 7, 2022 EMA Recommends Extension of Indications for Enzalutamide April 2, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... Young Man’s “Water You Can Eat” Invention for His Grandma with... Why it’s difficult to estimate the number of extra cancer deaths...
